Science & TechnologyImportant2026-03-17

CDSCO Approves Durvalumab Monotherapy for Liver Cancer

In News

What Happened

In March 2026, the Central Drugs Standard Control Organisation (CDSCO) approved an additional indication for AstraZeneca's Durvalumab as a monotherapy for liver cancer in India. Specifically, it was approved for patients with unresectable hepatocellular carcinoma (uHCC) who have not received prior systemic therapy. This decision officially sanctions the use of this monoclonal antibody for a new group of cancer patients.

Why It Matters

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and carries a very high mortality rate due to late diagnoses and limited treatment alternatives. The approval of Durvalumab provides a critical, much-needed immunotherapy option in India, directly addressing a major unmet medical need and potentially improving overall survival rates for advanced liver cancer patients.

Background

History & Context

Hepatocellular carcinoma accounts for the vast majority of primary liver cancers globally, strongly linked to chronic liver disease and hepatitis B and C infections. Prior to this, systemic therapy options for unresectable HCC in India were largely limited to standard multikinase inhibitors like Sorafenib. Durvalumab, a human monoclonal antibody that blocks the programmed death-ligand 1 (PD-L1) pathway, was previously approved globally and in India for other cancers (such as biliary tract cancer and non-small cell lung cancer), but data from the HIMALAYA Phase III clinical trial proved its efficacy as a standalone treatment for uHCC.

What Changed

▶
BEFORE: Systemic treatment options for unresectable HCC in India primarily relied on traditional multikinase inhibitors like Sorafenib or Lenvatinib as first-line therapies. NOW: Durvalumab is available as a monotherapy, providing a new, targeted immunotherapy option with potentially better tolerability for patients.
▶
BEFORE: AstraZeneca's Durvalumab was restricted in India to treating specific indications like biliary tract cancer and certain stages of lung cancer. NOW: The CDSCO has officially expanded its approved indications to include unresectable hepatocellular carcinoma (uHCC).
▶
BEFORE: Patients with uHCC had limited access to first-line single-agent immune checkpoint inhibitors targeting the PD-L1 pathway. NOW: Patients who have not received prior systemic therapy have direct access to this advanced PD-L1 blocking monoclonal antibody.

Prelims Angle

NCERT Connection

This development aligns with Class 12 Biology Chapter 8 (Human Health and Disease), specifically the sections on Cancer and Immunology. Durvalumab serves as a real-world application of immunotherapy, demonstrating how monoclonal antibodies (biological response modifiers) can be used to bypass the tumor's immune evasion mechanisms (like PD-L1) and assist the body's immune system in destroying the tumor.

Practice Questions

Q1

With Reference To

With reference to the recently approved Durvalumab monotherapy for liver cancer, consider the following statements: 1. Durvalumab is a monoclonal antibody that acts as an immune checkpoint inhibitor by targeting the PD-L1 pathway. 2. Unresectable hepatocellular carcinoma (uHCC) refers to early-stage liver cancer that can be easily completely removed through surgery. Which of the statements given above is/are correct?

Up next